Atossa Therapeutics (ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19.
I believe our innovative therapies and delivery methods can benefit COVID-19 patients and transform breast cancer treatment – with the goal of preventing breast cancer from developing in the first place” I will try to focus on a possible near term catalyst for the stock, which is about their Covid Nasal Spray, but their breast cancer treatments in the pipeline are also worth mentioning and researching for sure.
They currently have 2 COVID-19 therapeutic programs under development, one for severely ill patients on ventilators and another for at-home use in patients recently diagnosed with COVID-19 who do not require hospitalization.
What’s exciting about ATOS stock?
Their current Nasal Spray with AT301 is intended for at-home use to proactively reduce symptoms of COVID-19and to slow the infection rate so that a person’s immune system can more effectively fight SARS-CoV-2.
Atossa plans to identify potential partners who are developing COVID-19 diagnostic tests so that AT-301 nasal spray may be co-developed and commercialized with the goal of making the AT-301 therapy available at the time a person tests positive for the coronavirus.
Atossa also plans to develop its nasal spray to potentially help prevent COVID-19 infection — particularly for people in high-risk environments — including, for example, people living with a patient infected with COVID-19, healthcare workers, emergency responders, and teachers.
I managed to get specific information directly from the Clinical Trials Government website and apparently the study completion date was January 12th, 2021.
I looked for updates from official sources after the study completion and nothing popped up. What popped up instead, was actually a conference by PMWC (Precision Medicine World Conference) for January 26th.